

CIN: L72200TG1997PLC028374

To
Mr. Kautuk Upadhyay
Manager
National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai 400 051

Date: 19.09.2017

Dear Sir,

Sub: Non-compliance as per Reg.33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015
Ref: Your query letter vide No.NSE/LIST/19306 dated 14-Sep-2017

With reference to the cited subject and the above referred letter find point wise explanation for the queries raised therein:

S.No.	Observations	Our explanation
1	Reconciliation of profit and loss not submitted	Reconciliation of profit and loss is included in the revised Financial results
2	Standalone limited review report not submitted.	Standalone limited review report is enclosed
3	Financial results not submitted as per Schedule III to the Companies Act, 2013	Revised Financial results as per Schedule III to the Companies Act, 2013 are enclosed
4	Financial results not submitted within 30 minutes from end of board meeting.	The meeting of the Board of Directors concluded at 4.45 p.m. and the results were uploaded on NEAPS at 5.05 p.m. However, while mentioning the Board Meeting end time on neaps, erroneously we were mentioned as 4.45 instead of 16.45 (NSE Acknowledgment for results submission is enclosed)

We sincerely regret for the inconvenience caused. We undertake that in future we shall take utmost care while disseminating any information. In case you need any more information / explanation, the undersigned is obliged to furnish.

Thanking you
Yours truly

For Celestial Biolabs Limited


Dr A N Singh
(Chairman & Managing Director)
DIN: 01756827

CELESTIAL BIOLABS LIMITED
Plot No.59, Road No.12, TSIC Tech Park, IDA Nacharam, Hyderabad-500 076
Unaudited Financial Results for the Quarter Ended June,30th 2017

S.No.	Particulars	Rs In Lacs	
		Three months ended	
		30.06.2017 (Unaudited)	30.06.2016 (Unaudited)
I	Income from operations		
	a) Revenue from operations	604.73	1010.93
	b) Other Income	0.00	0.00
	Total income	604.73	1010.93
II	Expenditure		
	a) Cost of raw and packing materials consumed	9.41	342.29
	b) Purchase of Traded Products	204.32	438.05
	c) Changes of Inventories of Finished Goods, Work in Progress and Stock in Trade	35.61	24.30
	d) Employee Benefits Expense	15.48	22.42
	e) Depreciation and amortization	192.58	82.60
	g) Finance Cost	0.05	0.01
	h) Other Expenses	12.47	37.68
	Total expenses	469.92	947.35
III	Profit / (Loss) before exceptional and extra ordinary items (I-II)	134.81	63.58
IV	Exceptional items	0.00	0.00
V	Profit / (Loss) before tax (III - IV)	134.81	63.58
VI	Tax expense	25.69	12.11
VII	Net Profit / (Loss) for the period (V-VI)	109.12	51.47
VIII	Other Comprehensive Income, Total Other Comprehensive Income, net of Tax	0.00	0.00
IX	Total Comprehensive Income for the period	109.12	51.47
X	Paid-up Equity Share Capital (Face Value of Rs.10/- per share)	2258.63	2048.63
XI	Earning Per Share for the Period		
	Basic	0.48	0.25
	Diluted	0.48	0.23

Notes

- The Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13.09.2017
- This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April, 1, 2017 the Company has for the first time adopted Ind AS with a transition date of April, 1, 2017.
- The Company is engaged in the business of "Herbal Products" and therefore, has only one reportable segment in accordance with Ind AS 108 "Operating Segment".
- The Statement does not include Ind AS Complaint results for the preceding quarter and previous year ended March 31, 2017 as the same is not Mandatory as per SEBI's circular dated July 5, 2016.
- The Financial results and other financial information for the quarter ended 30th June, 2016 has been compiled by the management as per Ind AS, after exercising necessary due diligence, to ensure that the financial results provide true and fair view of the results in accordance with Ind AS. This information has not been subject to any limited review or audit.
- Reconciliation of Profit between Ind-AS and Indian GAAP for the quarter ended June 30, 2016 is as follows:

In Lakhs	
Particulars	Amount
Profit/Loss as per previous GAAP	51.47
Net Profit as per Ind - AS	51.47

HYDERABAD
Date: 13.09.2017





LAKSHMI PURNA & ASSOCIATES
Chartered Accountants

Plot No. 131, Flat No.202,
Murthy Mansion Apts., Bhagyanagar Colony,
Kukatpally, Hyderabad - 500 072.
Off : 040-40258773, Cell : 97034 79997
lakshmipurna22622@yahoo.com

The Board of Directors
Celestial Biolabs Limited,
Plot No.59, Road No.12,
TSIIC Tech Park, Nacharam,
Hyderabad – 76
Dear Sir,

Sub: Report on Limited Review of the Un-Audited Financial Result of the Company for the Quarter ended 30th June,2017.

1. We have reviewed the accompanying Statement of unaudited Financial Results of Celestial Biolabs Limited' (the 'Company') for the quarter ended 30th June,2017 (the statement), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 as modified by circular No. CIR/CFD/FAC/62/2016, dt. July, 5, 2016. This Statement which is responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under section 133 of the Companies Act,2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and , accordingly we do not express an audit opinion.
4. Based on our review conducted as above and subject to the observations in Paragraph 5, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations,2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to the following matters:
 - a. The Company has adopted Ind AS for the Financial Year commencing from 1st April, 2017 and the Statement has been prepared by the Company's Management in Compliance with Ind AS.
 - b. We were neither engaged to review , nor have we reviewed the comparative figures including the reconciliation to the Total Comprehensive Income for the quarter ended 30th June, 2017 and accordingly we do not express any conclusion on the results in the Statement for the quarter ended 30th June,2017.

Our Conclusion is not qualified in respect of these matters.

LAKSHMI PURNA AND ASSOCIATES
Chartered Accountants

(CH. L. PURNACHANDRAN) Proprietor
Membership No.221392



Place: Hyderabad
Date: 13/09/2017



Date of Download 19-Sep-2017

NSE Acknowledgement

Symbol:-	CELESTIAL
Name of the Company: -	Celestial Biolabs Limited
Submission Type:-	Results
Quarter/Period Ended: -	2017-06-30 00:00:00
Date of Submission:-	13-Sep-2017 17:05:38
NEAPS App. No:-	30880

Disclaimer :We hereby acknowledge receipt of your submission through NEAPS. Please note that the content and information provided is pending to be verified by NSEIL.